
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep is in a strong position with a diversified product portfolio that caters to both cancer and autoimmune disease treatments. With efti showing promising results in Phase 3 trials and multiple partnerships for its development, the company has a strong potential for growth in the long term. Additionally, the company's collaborations and partnerships demonstrate their ability to leverage their product portfolio and maximize the potential of efti in different markets, further contributing to their potential success in the future. The company's strong patent portfolio and manufacturing partnership also provide stability and potential for competitive advantage in the market.
Bears say
Immutep is facing a high level of risk due to its focus on a single drug, efti, and its reliance on a single Phase three clinical trial for marketing approval in first-line NSCLC treatment. Additionally, the company's other product candidates are still in early development stages, and their potential for success is uncertain at this time. Immutep also faces competition from other established companies in the immunotherapy space, which could impact market penetration and commercial success. These factors, combined with the regulatory uncertainty, lead to a negative outlook on Immutep's stock.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares